Healthcare Events

25/08/2026

𝐏𝐫𝐨𝐠𝐫𝐚𝐦 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭 𝐟𝐨𝐫 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬

𝐖𝐞𝐛𝐢𝐧𝐚𝐫 𝐨𝐧 𝐄𝐥𝐞𝐜𝐭𝐫𝐢𝐜𝐚𝐥 𝐒𝐚𝐟𝐞𝐭𝐲 𝐢𝐧 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬 𝐚𝐧𝐝 𝐂𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐂𝐚𝐫𝐞 𝐀𝐫𝐞𝐚𝐬

Organised by:

The National Federation of Engineers for Electrical Safety (NFE)

NFE invites Hospital Administrators & Professionals to a special knowledge webinar focusing on Electrical Safety in Hospitals & Critical Care Areas.

Date, Time: 28th Aug 2026, Friday | 4:00 PM IST

Speaker: S. Gopa Kumar, President – NFE

Register for online webinar:

https://us02web.zoom.us/webinar/register/WN_Yuuwnq5WRKWDs4zB9cAZ-g #/registration

National Federation Of Engineers for Electrical Safety

15/08/2026

Celebrating 80 years of freedom, strength, and resilience!

🇮🇳 From economic milestones to standing by the world in times of need, India's growth is fueled by unity and compassion.

Happy Independence Day to all! 🌟🙏

23/07/2026

President Trump announced a stepped, multi-year tariff schedule specifically targeting imported generic drugs. By providing a 2-year reprieve before imposing steep levies (100% in 2028, rising to 200% in 2029), the administration aims to force pharmaceutical companies to build manufacturing plants within the United States.
While the policy is framed as a penalty for companies that fail to "reshore" domestic production, industry experts and trade policy analysts question whether a 2-year runway is realistic or economically viable for the low-margin generic drug sector.

Key Highlights from the announcement :
1. The Tariff Timeline
Aug 2026 – Aug 2028: 0% tariff (a 2-year transition window).
Aug 2028: Tariff rises to 100%.
Aug 2029: Tariff doubles to 200%.
Scope: Applies only to generic drugs. Patented, branded, and innovative drug tariffs remain unchanged.

2. India and China Face High Exposure
India: Indian drugmakers supply nearly 50% of all generic medicines consumed in the U.S. (accounting for ~1/3 of India's total pharmaceutical exports). Analysts note this poses significant commercial and trade balance risks for New Delhi.
China: China dominates upstream manufacturing of Active Pharmaceutical Ingredients (APIs) (e.g., amoxicillin and heparin), meaning U.S. supply chains remain deeply tied to foreign inputs even if final assembly occurs elsewhere.

3. Feasibility & Market Dynamics
Is 2 Years Enough? Trade experts point out that building and validating U.S. pharma plants is exceptionally capital-intensive and time-consuming. Because raw inputs must still be imported, critics doubt even a 200% tariff will fundamentally alter the economics of generic manufacturing.

Risk of Product Discontinuations: Generic margins are already razor-thin. If domestic wholesalers refuse to absorb tariff-driven price increases, manufacturers may simply stop producing lower-profit essential drugs rather than build U.S. facilities, worsening potential drug shortages in USA

4. Broader Trade & Industry Context
Section 232 & MFN Deals: Earlier trade actions placed a 100% levy on patented pharma imports, though major drugmakers (e.g., Eli Lilly, Pfizer, Novo Nordisk) secured 3-year tariff exemptions by signing onto Most-Favored-Nation (MFN) drug pricing agreements.
Next Steps for Indian Drug Manufacturers:

Indian drugmakers and trade associations (like the Indian Pharmaceutical Alliance) are expected to pursue a multi-pronged approach: lobbying Washington for product-level exemptions, accelerating FDA approvals, pursuing U.S. contract manufacturing partnerships, and seeking alternative export markets.

President Trump announces a zero tariff on imported generic drugs through August 2026 before a phased escalation to 200% by 2029.

10/07/2026

🚀 Big News in Healthcare & IVF! 🚀

Chennai-based Iswarya Fertility Center has officially raised over ₹350 Crore (nearly $37 Million) in a milestone growth investment from healthcare private equity giant OrbiMed Asia.

This massive funding marks a significant moment as institutional investors increasingly focus on India's expanding fertility care market.

✨ Key Highlights of the Deal:

🏥 Fueling Expansion: The capital will be used to launch new fertility centers in existing and underserved markets across India.

🧬 Upgrading Infrastructure: Investments will pour into strengthening clinical infrastructure, upgrading digital capabilities, and expanding their embryology talent pipeline.

🌐 Global Ambitions: While the immediate focus remains on deepening their pan-India presence, the management has indicated plans to eventually expand into international markets.

📈 An Elite Footprint: Founded in 1986, Iswarya has grown to become Southern India’s largest fertility network, operating 85+ centers across 8 states and serving over 300,000 couples.

💡 Market Insight:
India’s shifting demographic trends—highlighted by the national total fertility rate dipping to 1.9 (below the 2.1 replacement rate)—combined with rising urban incomes, are driving unprecedented demand and investor interest in high-quality fertility treatment.

The capital will fund new centres, clinical infrastructure and digital capabilities as investor interest in India's fertility care sector gathers pace.

09/07/2026

🚨 Regulatory Alert:
DCC Proposes Strict Public Disclosure for Pharma Non-Compliance & Recalls

To bridge the enforcement gap between state and central drug regulators, the Drugs Consultative Committee (DCC) under the CDSCO has recommended a significant transparency mandate that will directly impact pharmaceutical operations and procurement workflows across India.

Key Highlights of the Proposed Directives:

🌐 Mandatory Public Disclosure: State drug authorities must publish all orders relating to license suspensions, cancellations, "stop production," or drug recalls directly on their official websites.

🗓️ Strict Monthly Deadlines: State regulators will be required to share details of these enforcement actions and complete Not of Standard Quality (NSQ) drug lists with the CDSCO before the 10th of every month.

📦 Packaging Supply Chain Oversight: The DCC has also proposed a sub-committee to explore a regulatory framework for registering all printed packaging material suppliers to curb the diversion of materials into counterfeit/spurious medicines.

Why This Matters for Stakeholders:

Procurement Integrity: The move aims to prevent non-compliant manufacturers from using photocopies of canceled product licenses to secure fresh supply and procurement orders.

Supply Chain Visibility: Real-time online data ensures that a drug recall or quality issue triggered in one state is instantly visible to distributors, pharmacies, and healthcare professionals nationwide.

Reputational Accountability: Public "naming and shaming" places an increased premium on robust Quality Assurance (QA) and strict adherence to manufacturing standards.

Enforcement alignment is shifting toward absolute transparency. Stakeholders across the supply chain must prepare for tighter scrutiny and faster public data sharing.

An expert panel has recommended that states publish all regulatory actions online and share monthly enforcement data with the central drug regulator to improve transparency

05/07/2026

Union Health Ministry sent a letter to States mandating a special fire safety audit drive for all public and private healthcare facilities, which must be completed and uploaded to the Ministry's Integrated Health Information Platform (IHIP) by July 31 2026

Mandatory Monthly Audits:
While over 4,000 facilities completed audits in May, the Center is now making these audits a strict, monthly routine for all hospitals, including private nursing homes.

Focus Areas:
The directive heavily emphasizes checking high-risk environments where patients are most vulnerable and less mobile, specifically ICUs, NICUs (Neonatal Intensive Care Units), nurseries, and other critical care units.

Trigger Event:
This national directive follows a recent fire incident in the operation theatre of the Chigateri District Hospital in Davangere, Karnataka (though luckily, no casualties occurred as surgeries hadn't started yet).

Guidelines Dissemination:
States are instructed to widely distribute the updated National Guidelines on Fire and Life Safety in Healthcare Facilities to make sure every hospital knows exactly what protocols to follow.

The decision from the central government aims to solve a historically reactive problem with two primary objectives:

Shift from Reactive to Proactive (Routine Integration): The primary goal is to shift fire safety from being a "one-time, check-the-box exercise" (usually done only after a tragedy happens) into a fundamental, routine part of everyday hospital management and patient safety protocols.

Protect Vulnerable Patients: By forcing a strict focus on ICUs and newborn nurseries, the objective is to dramatically lower the risk of mass casualties in areas where patients are completely dependent on staff and machinery to survive, ensuring that the infrastructure supporting them is structurally fire-safe.

The Union Ministry of Health and Family Welfare has directed all States and Union Territories to complete fire safety audits of all public and private healthcare facilities through a special drive and upload the findings on the Integrated Health Information Platform (IHIP) by July 31

26/06/2026

📢 𝐂𝐃𝐒𝐂𝐎 𝐒𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐞𝐧𝐬 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐎𝐯𝐞𝐫𝐬𝐢𝐠𝐡𝐭 𝐨𝐧 𝐈𝐕𝐅 𝐂𝐨𝐧𝐬𝐮𝐦𝐚𝐛𝐥𝐞𝐬

The Central Drugs Standard Control Organisation (CDSCO) has issued an important circular directing that IVF media, reagents and related consumables used in Assisted Reproductive Technology (ART) procedures be supplied only to centres registered under the Assisted Reproductive Technology (Regulation) Act, 2021 and the Surrogacy (Regulation) Act, 2021.

This notification marks a significant step in strengthening India's reproductive healthcare ecosystem by extending regulatory oversight beyond healthcare providers to the supply chain itself.

The circular is expected to:

✔ Strengthen implementation of the ART and Surrogacy Acts, 2021
✔ Improve patient safety and quality assurance
✔ Promote ethical reproductive healthcare practices
✔ Enhance traceability and accountability in the supply of IVF consumables
✔ Reinforce regulatory compliance across manufacturers, importers, distributors and ART clinics

As India's fertility treatment sector continues to grow, this move reflects the Government's commitment to ensuring that Assisted Reproductive Technology services are delivered through legally registered and compliant centres.

We have published a detailed article explaining the background, regulatory significance, and implications of this important CDSCO notification.

📄 Read the full post for more detailed explanation, the background, regulatory significance, and implications of this important CDSCO notification.

CDSCO Tightens Control on IVF Consumables by Restricting Supplies to Registered Fertility Centres The CDSCO circular is not merely an administrative instruction on the sale of IVF consumables. It i…

31/03/2026

📢 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐔𝐩𝐝𝐚𝐭𝐞: 𝐍𝐞𝐰 𝐂𝐃𝐒𝐂𝐎 𝐀𝐝𝐝𝐞𝐧𝐝𝐮𝐦 𝐟𝐨𝐫 𝐈𝐕𝐃 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 📢

The Central Drugs Standard Control Organization (CDSCO) has released Addendum No. 02 to the FAQs on In-Vitro Diagnostic (IVD) Medical Device Regulations

If you are a manufacturer, importer, or regulatory professional in the IVD space, here is what you need to know about the latest updates to the Medical Devices Rules, 2017:

✅ License Retention: Endorsements and base licenses must now be retained simultaneously.

✅ Site Relocation: Any change in the location of a domestic manufacturing site now requires a mandatory QMS re-inspection for a fresh license.

✅ Product Applications: To avoid delays, CDSCO advises limiting applications to 15 products per submission.

✅ Software Updates: Version changes or updates to approved software must be submitted via a Post-Approval Change (PAC) application.

✅ Veterinary IVDs: Clinical Performance Evaluation (CPE) is officially not required for new Veterinary IVDs.

⚠️ Deadline Alert: Don’t ignore portal alerts! Applications will be deemed withdrawn if no response is submitted after the 4th automated reminder.

Addendum Release Date: March 13, 2026.

Reference Doc No: CDSCO/IVD/FAQ/04/2022.

Stay compliant and keep your registrations up to date! 🛡️

More information at :

In-Vitro Diagnostic (IVD) Medical Devices Division, Frequently Asked Questions – released by CDSCO – Addendum No.:02, dated 13.03.2026 Update: CDSCO Releases New Addendum on IVD Medical…

03/03/2026

🚨 Major Regulatory Alert:
CDSCO is moving toward a 'Notified Body' model for drug audits!

By partnering with QCI and planning a recruitment drive for 1,500 new personnel, the DCGI is aiming to put India’s regulatory oversight on par with the US FDA and EMA. Here’s what this means for manufacturing compliance.

Key Takeaways from the Post :
Engagement of Notified Bodies: CDSCO will formally involve third-party "notified bodies" certified by the QCI to conduct various drug regulatory audits.

Shift from Government-Only Audits: Traditionally, audits were restricted to drug inspectors from the CDSCO or State Regulatory Authorities. This move opens the door for accredited private/third-party entities to participate in the oversight process.

Modeled on Global Standards: The framework is inspired by the European Medicines Agency (EMA) model, where notified bodies evaluate medical devices and grant certifications (like the CE mark) before products enter the market.

Massive Manpower Expansion: Alongside outsourcing audits, CDSCO plans to recruit approximately 1,500 new personnel to strengthen its internal scientific review capacity and reduce dependence on external subject expert committees.

Approval Status: The government has granted "in-principle" approval, and the CDSCO is currently in the final stages of formalizing the engagement framework with the QCI.

Why is CDSCO collaborating with QCI ?

The collaboration is driven by a need to modernize India’s regulatory infrastructure and address several critical bottlenecks:

1. Addressing Manpower and Capacity Gaps
2. Improving Audit Coverage and Frequency
3. Enhancing Technical Expertise
4. Building "Institutional Memory"
5. Achieving Global Parity

The ultimate goal is to make India’s regulatory system as robust as the US FDA or the EMA. By adopting the "notified body" system used in Europe, India aims to reinforce global confidence in the quality and safety of Indian-made pharmaceuticals, which is vital for the country's status as the "pharmacy of the world."

CDSCO soon to engage QCI certified notified bodies to augment drug regulatory audit capacity: DCGI